



**February 21, 2024**

To,  
Listing Operations Department,  
**BSE Limited,**  
P.J. Towers, Dalal Street  
Mumbai – 400 001.

**BSE Scrip Code: 531592**  
**ISIN: INE861N01036**

**Subject: Outcome of the Right Issue Committee - Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "SEBI Listing Regulations")**

**Dear Sir,**

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), we would like to inform you, that pursuant to the finalization of the basis of allotment of the Rights Issue as approved by BSE Limited ("BSE"), the designated stock exchange for the Rights Issue on February 21, 2024, the Rights Issue Committee at its meeting held on February 21, 2024 has considered and approved the allotment of 27,68,59,850 Rights Equity Shares fully paid up at an issue price of Rs. 1.75 per Rights Equity Share (including a premium of Rs. 0.75 per equity share) to the eligible equity shareholders in the Issue. The above is for your information and dissemination to the members. We request you to take the above on record and that the same be treated as compliance under the applicable regulation(s) under the SEBI Listing Regulations.

The Meeting concluded at 07:35 P.M.

You are requested to take the above on record and acknowledge.

Thanking you,

Yours faithfully,

**For Genpharmasec Limited**

ULHAS  
NARAYAN  
DEOSTHALE  
Digitally signed by  
ULHAS NARAYAN  
DEOSTHALE  
Date: 2024.02.21  
19:46:04 +05'30'

**Ulhas Deosthale**  
**Whole Time Director**  
**DIN: 09215291**

